BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34593466)

  • 1. Second-line Chemotherapy for Previously Treated Metastatic Small Bowel Adenocarcinoma: A Retrospective Analysis.
    Nakazawa T; Narita Y; Kumanishi R; Ogata T; Matsubara Y; Nozawa K; Kato K; Honda K; Masuishi T; Bando H; Kadowaki S; Ando M; Hara K; Tajika M; Muro K
    Anticancer Res; 2021 Oct; 41(10):5147-5155. PubMed ID: 34593466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological features and treatment outcomes of metastatic or locally unresectable small bowel adenocarcinoma.
    Li X; Ying H; Cheng Y; Zhao L; Zhao S; Bai C; Zhou J
    J BUON; 2019; 24(6):2539-2545. PubMed ID: 31983130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma.
    Overman MJ; Kopetz S; Wen S; Hoff PM; Fogelman D; Morris J; Abbruzzese JL; Ajani JA; Wolff RA
    Cancer; 2008 Oct; 113(8):2038-45. PubMed ID: 18759326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study.
    Legué LM; van Erning FN; Bernards N; Lemmens VEPP; de Hingh IHJT; Creemers GJ
    Target Oncol; 2019 Dec; 14(6):699-705. PubMed ID: 31625001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO).
    Aydin D; Sendur MA; Kefeli U; Umut Unal O; Tastekin D; Akyol M; Tanrikulu E; Ciltas A; Bala Ustaalioglu B; Sener Dede D; Esbag O; Inal A; Bilir C; Bilici A; Harputlu H; Berk V; Sevinc A; Yildirim Ozdemir N; Yildirim E; Sonkaya A; Ali Ustaoglu M; Gumus M
    J BUON; 2016; 21(5):1242-1249. PubMed ID: 27837629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy for small-bowel Adenocarcinoma at a single institution.
    Suenaga M; Mizunuma N; Chin K; Matsusaka S; Shinozaki E; Oya M; Ueno M; Yamaguchi T; Muto T; Konishi F; Hatake K
    Surg Today; 2009; 39(1):27-31. PubMed ID: 19132464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study.
    Gulhati P; Raghav K; Shroff RT; Varadhachary GR; Kopetz S; Javle M; Qiao W; Wang H; Morris J; Wolff RA; Overman MJ
    Cancer; 2017 May; 123(6):1011-1017. PubMed ID: 27859010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy.
    Tsushima T; Taguri M; Honma Y; Takahashi H; Ueda S; Nishina T; Kawai H; Kato S; Suenaga M; Tamura F; Morita S; Boku N
    Oncologist; 2012; 17(9):1163-70. PubMed ID: 22622149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Prognostic Factors in Resected Small Bowel Adenocarcinoma.
    Huffman BM; Jin Z; Yadav S; Patel S; Nagorney DM; Truty MJ; McWilliams RR; Halfdanarson TR; Mahipal A
    Clin Colorectal Cancer; 2019 Sep; 18(3):218-225. PubMed ID: 31178274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection.
    Aydin D; Sendur MA; Kefeli U; Unal OU; Tastekin D; Akyol M; Tanrikulu E; Ciltas A; Ustaalioglu BB; Uysal M; Esbag O; Yazilitas D; Tanrıverdi O; Bilici A; Arpaci E; Berk V; Yetisyigit T; Ozdemir NY; Oztop I; Alacacioglu A; Aydin O; Ozcelik M; Yildirim E; Dinc N; Gumus M
    Clin Colorectal Cancer; 2017 Sep; 16(3):220-227. PubMed ID: 27670893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.
    McWilliams RR; Foster NR; Mahoney MR; Smyrk TC; Murray JA; Ames MM; Horvath LE; Schneider DJ; Hobday TJ; Jatoi A; Meyers JP; Goetz MP
    Cancer; 2017 Sep; 123(18):3494-3501. PubMed ID: 28493308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palliative chemotherapy for patients with synchronous metastases of small-bowel adenocarcinoma: A reflection of daily practice.
    Legué LM; Bernards N; Lemmens VE; de Hingh IH; Creemers GJ; van Erning FN
    United European Gastroenterol J; 2019 Dec; 7(10):1380-1388. PubMed ID: 31839964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine.
    Ono M; Shirao K; Takashima A; Morizane C; Okita N; Takahari D; Hirashima Y; Eguchi-Nakajima T; Kato K; Hamaguchi T; Yamada Y; Shimada Y
    Gastric Cancer; 2008; 11(4):201-5. PubMed ID: 19132481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.
    Takayoshi K; Kusaba H; Uenomachi M; Mitsugi K; Makiyama C; Makiyama A; Uchino K; Shirakawa T; Shibata Y; Shinohara Y; Inadomi K; Tsuchihashi K; Arita S; Ariyama H; Esaki T; Akashi K; Baba E
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):333-342. PubMed ID: 28653251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study.
    Zaanan A; Gauthier M; Malka D; Locher C; Gornet JM; Thirot-Bidault A; Tougeron D; Taïeb J; Bonnetain F; Aparicio T;
    Cancer; 2011 Apr; 117(7):1422-8. PubMed ID: 21425142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy in advanced small bowel adenocarcinoma.
    Locher C; Malka D; Boige V; Lebray P; Elias D; Lasser P; Ducreux M
    Oncology; 2005; 69(4):290-4. PubMed ID: 16282708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma.
    Aldrich JD; Raghav KPS; Varadhachary GR; Wolff RA; Overman MJ
    Oncologist; 2019 Jun; 24(6):e384-e386. PubMed ID: 30598498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of small bowel adenocarcinoma in Crohn's disease compares favourably with de novo small bowel adenocarcinoma.
    Wieghard N; Mongoue-Tchokote S; Young JI; Sheppard BC; Tsikitis VL
    Colorectal Dis; 2017 May; 19(5):446-455. PubMed ID: 27659145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency.
    Czaykowski P; Hui D
    Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):143-9. PubMed ID: 17355111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.
    Zaanan A; Costes L; Gauthier M; Malka D; Locher C; Mitry E; Tougeron D; Lecomte T; Gornet JM; Sobhani I; Moulin V; Afchain P; Taïeb J; Bonnetain F; Aparicio T
    Ann Oncol; 2010 Sep; 21(9):1786-1793. PubMed ID: 20223786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.